AADC Deficiency clinical trials at University of California Health
2 in progress, 1 open to eligible people
Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
open to eligible people ages 24 months and up
The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency.
Sorry, in progress, not accepting new patients
The objective of this study is to assess the safety of VY-AADC02 in participants with Parkinson's disease (PD) with motor fluctuations.
at UC Davis UC Irvine UCSF
Our lead scientists for AADC Deficiency research studies include Nalin Gupta, MD.